Haematology & Oncology Flashcards
(164 cards)
What is the most likely diagnosis?
What biochemical defect is responsible for this condition?
Acute intermittent porphyria (AIP).
AIP is caused by a deficiency in
porphobilinogen deaminase (also known as hydroxymethylbilane synthase), an enzyme required for hemoglobin production. Typically, patients have accumulation of porphobilinogen and present with neuropathy and attacks of abdominal pain caused by precipitants that increase α-aminolevulinic acid (ALA) synthase activity. ALA production from glycine and succinyl CoA by ALA synthase is the rate-limiting step of heme production. As a result, any increase in ALA production leads to more AIP symptoms (Figure 8-1).
What are the most likely precipitants of this patient’s attacks?
Precipitants that increase ALA synthase activity include the following:
1. Endogenous/exogenous gonadal steroids.
2. Low-calorie diets.
3. Drugs (sulfonamides, antiepileptic agents).
4. Stress.
5. Alcohol.
What other condition should be considered if the patient has neurologic manifestations but no abdominal pain?
Ascending muscle weakness with hyporeflexia or areflexia is the classic presentation of Guillain-Barré syndrome. However, the high level of porphobilinogen in the urine of this patient is essentially pathognomonic for AIP. If the diagnosis is unclear, a lumbar puncture can be performed. Albuminocytologic dissociation is seen in the cerebrospinal fluid of patients with Guillain-Barré syndrome. Other possible causes of peripheral muscle weakness include muscle atrophy, leprosy, myeloma, lead poisoning, and diabetes.
What is the appropriate treatment for Acute intermittent porphyria (AIP)?
Heme, as the end product of the biosynthetic pathway, is a repressor of ALA synthase. Therefore, an intravenous injection of hemin (IV heme) decreases synthesis of ALA synthase via negative feedback and often reduces the severity of symptoms. Intravenous infusion of dextrose solution can also help abate acute attacks. Hemin is used for refractory cases after failure of carbohydrate loading. Treatment of pain and monitoring for neurologic and respiratory compromise are essential.
What is the most likely diagnosis? What conditions should be considered in the differential diagnosis?
Acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood. The classic presentation and laboratory findings include fever (the most common sign), fatigue, lethargy, bone pain, arthralgia, and elevated serum lactate dehydrogenase (LDH). Less common symptoms include headache, vomiting, altered mental function, oliguria, and anuria.
What is the etiology of the physical examination findings in this patient with acute lymphoblastic leukemia?
Most findings derive from leukemic expansion and crowding out of the normal marrow. This causes anemia and thrombocytopenia as well as bone or joint pain from invasion into the periosteum. Fever results from pyrogenic cytokines released from leukemic cells. Elevated LDH is a consequence of increased cellular turnover. Painless enlargement of the scrotum and central nervous system symptoms may also be signs of more extensive extramedullary invasion.
What is the appropriate treatment for Acute lymphoblastic leukemia (ALL)?
Complex chemotherapy regimens are standard and divided into induction, consolidation, and maintenance phases. Most regimens involve combinations of cyclophosphamide, doxorubicin, vincristine, dexamethasone/prednisone, methotrexate, asparaginase, and cytarabine. Recent advances in treatment have resulted in complete remission rates as high as 80% in children with ALL.
What is the most likely diagnosis?
What cells are affected in this condition?
What other symptoms are common at presentation in this condition?
Acute myelogenous leukemia (AML) is the most common acute leukemia in adults. The median age of diagnosis in the United States is 65 years.
AML is a neoplasm of myelogenous progenitor cells. The progenitor cells may appear as granulocyte precursors, monoblasts, megakaryoblasts, or erythroblasts.
What are the likely bone marrow biopsy findings in Acute myelogenous leukemia (AML)?
The proliferation of myeloblasts with characteristic eosinophilic, needle-like cytoplasmic inclusions, or Auer rods, is pathognomonic for AML (Figure 8-3).
How can genetic testing influence treatment of Acute myelogenous leukemia (AML)?
Genetic abnormalities are critical in the diagnosis and treatment of AML. For example, t(15;17) chromosomal translocation indicates acute promyelocytic leukemia (M3 variant) as the specific diagnosis. This can be treated with targeted drugs such as all-trans retinoic acid, which differentiates promyelocytes into mature neutrophils, thereby inducing apoptosis of the leukemic promyelocytes. This results in a high likelihood of remission and cure.
Why is cellulitis commonly associated with Acute myelogenous leukemia (AML)?
Neutropenia caused by replacement of mature WBCs with leukemic cells increases susceptibility to infection.
What is the most likely diagnosis? What is the most likely cause of this patient’s condition?
Aplastic anemia results from bone marrow failure or autoimmune destruction of myeloid stem cells, which leads to pancytopenia. Pancytopenia affects all cell lines, resulting in neutropenia, anemia, and thrombocytopenia, all of which are seen on a complete blood count.
What other test can help confirm the diagnosis of aplastic anaemia?
Bone marrow biopsy reveals hypocellular bone marrow (< 30% cellularity) with a fatty infiltrate. Figure 8-4A shows a normal bone marrow biopsy; Figure 8-4B shows a biopsy sample from a patient with aplastic anemia.
What is the appropriate treatment for Aplastic anemia?
Initial treatment is to withdraw any possible toxic agent causing the condition. Supportive care, including antibiotics for infection and blood transfusion if symptoms develop, is also important. If testing reveals severe depression of one or several cell lines, definitive therapy, including stem cell transplantation or immunosuppression, is appropriate. If possible, transfusion should be avoided before bone marrow transplantation because of the risks of alloimmunization and graft rejection.
What is the most likely diagnosis?
β-Thalassemia major is the homozygous form of the genetically transmitted disease β-thalassemia, where the β-globin gene of hemoglobin is mutated, resulting in microcytic anemia. It is prevalent in Mediterranean populations.
By contrast, in α-thalassemia, α-globin genes in hemoglobin are deleted; this condition is most commonly present in Southeast Asians and blacks.
What mutations are present in α-thalassemia and in β-Thalassemia major?
Humans have two α-globin genes on chromosome 16, resulting in four alpha alleles. α-Thalassemia results
in four types of thalassemia, depending on the number of alpha allele deletions that occur. Increasing severity results from increasing numbers of deletions. These deletions result from unequal meiotic crossover between adjacent alpha genes.
Humans have one β-globin gene on chromosome 11, resulting in two beta alleles. In β-thalassemia, beta allele mutations, rather than deletions, occur. These mutations can occur in the promoter, exon, intron, or polyadenylation sites. Some mutations may produce no β-globin, whereas others may produce a small amount.
What are the symptoms and signs of β-thalassemia major?
Symptoms of β-thalassemia major emerge after approximately 6 months of life and are due to the decline in γ-hemoglobin production without a rise in β-hemoglobin production. The early signs and symptoms include pallor, growth retardation, hepatosplenomegaly, and jaundice.
How is β-thalassemia diagnosed?
Definitive laboratory testing using gel electrophoresis is used for diagnosis, as it can distinguish mutated and normal forms of hemoglobin. An increased concentration of fetal haemoglobin (HbF) may also be seen on electrophoresis. Notably, an increase in HBA2 is seen in β-thalassemia minor.
What is the appropriate treatment for β-thalassemia major?
β-Thalassemia major causes severe anemia. HbF induction may be used. Treatment with repeated blood transfusions may also be required. Subsequently, iron chelation for overload is important. Splenectomy may be necessary to treat the resulting hypersplenism. Stem cell transplantation may also be used in selected cases. β-Thalassemia minor is usually asymptomatic and its treatment requires only avoidance of oxidative stressors of RBCs.
What is the most likely diagnosis?
What does the positive Coombs test indicate?
Warm autoimmune hemolytic anemia (WAIHA) secondary to SLE. Most cases of this condition are idiopathic or associated with autoimmune processes, lymphoproliferative disorders, or drugs.
The positive Coombs test indicates the presence of antibodies against RBCs, which can cause hemolysis.
What is the difference between a direct and indirect Coombs test?
The difference between the direct and indirect Coombs test is where the antibodies against RBCs are detected. In a positive direct Coombs test, antibodies are detected directly on RBCs. This occurs in WAIHA, called such because a positive agglutination test will be present at 37°C (98.6°F). In a positive indirect Coombs test, antibodies are detected in the serum. This occurs at 4°C (39.2°F), which is why this is referred to as cold hemolytic anemia.
What are other causes of Warm autoimmune hemolytic anemia (WAIHA) other than SLE?
The two most common causes are primary (idiopathic) and secondary due to such underlying conditions as autoimmune disorders, such as SLE. Medications (methyldopa), lymphomas, and leukemias are also common triggers.
What is the pathogenesis of Warm autoimmune hemolytic anemia (WAIHA)?
This is typically an IgG-mediated process. IgG coats RBCs and acts as an opsonin, such that the RBCs are phagocytized by monocytes and splenic macrophages.
When medications are the underlying cause, the hapten model has been suggested. RBC-bound drugs are recognized by antibodies and targeted for destruction.
What is the other form of autoimmune hemolytic anemia (AIHA)?
Cold agglutinin hemolytic anemia is the other form, and it occurs when IgM antibodies bind, fix complement, and agglutinate RBCs at low temperatures. These antibodies typically appear acutely following certain infections such as mononucleosis and Mycoplasma. This disease is usually self-limited but treatment-resistant forms exist. Clinical manifestations include pallor and cyanosis of distal extremities exposed to cold temperatures; this is secondary to vascular obstruction from complement deposition.